Peritonitis
INFLAMMATION of the PERITONEUM lining the ABDOMINAL CAVITY as the result of infectious, autoimmune, or chemical processes. Primary peritonitis is due to infection of the PERITONEAL CAVITY via hematogenous or lymphatic spread and without intra-abdominal source. Secondary peritonitis arises from the ABDOMINAL CAVITY itself through RUPTURE or ABSCESS of intra-abdominal organs.
Subtype terms (2)
More specific conditions that are subtypes of Peritonitis in the MeSH hierarchy.
Drugs by status
Approved for this indication (9)
Phase 4 trials (31)
- metronidazole
- propofol
- cefotaxime
- dextran
- echinocandins
- albumin (Human)
- icodextrin
- tigecycline
- nitazoxanide
- norfloxacin
- potassium chloride
- propranolol
- ceftriaxone
- dalbavancin
- risedronate
- sorbitol
- sulbactam
- vancomycin
- ciprofloxacin
- autologous microbiome
- carvedilol
- human fecal microbiota
- dexmedetomidine
- gentamicin
- cefoperazone
- midazolam
- lactic acid
- ertapenem
- calcium chloride
- colistin
- +1 more
Phase 3 trials (20)
- allopurinol
- procaine benzylpenicillin
- clavulanate
- doripenem
- gemifloxacin
- daptomycin
- itropride
- atorvastatin
- rifaximin
- sulfamethoxazole
- bifidobacterium infantis
- bifidobacterium breve
- bifidobacterium longum
- lactobacillus plantarum
- vsl #3
- streptococcus salivarius
- meropenem
- Lactobacillus acidophilus
- lactobacillus casei
- lactobacillus delbrueckii
Phase 2 trials (3)
Organizations
Organization Involved with Phase 4 Indications (22)
- Wyeth
- Centre Hospitalier Universitaire de Nīmes
- Chulalongkorn University
- Cornell University
- Hôpital Raymond Poincaré
- Korea University
- National Cheng Kung University
- University of Virginia
- Chinese University of Hong Kong
- University of Colorado, Denver
- The University of Hong Kong
- University of Barcelona
- Soonchunhyang University
- Kyungpook University
- University of Paris
- University of Brescia
- The Kidney Foundation of Thailand
- Siam Pharmaceutical Co Ltd
- Sungkyunkwan University
- Pro-bio Biotech Co. Ltd.
- American Association for the Study of Liver Diseases
- Yuria-Pharm
Organization Involved with Phase 3 Indications (24)
- Peninsula Pharmaceuticals
- University of London
- Govind Ballabh Pant Institute of Postgraduate Medical Education and Research
- Seoul National University
- Tanta University
- University of Padova
- All India Institute of Medical Sciences
- University of Haifa
- University of Toulouse
- University of Lille
- University of Reims
- University of Nice Sophia Antipolis
- Alfa Wassermann
- National Institute for Health Research, United Kingdom
- Eurofins
- Fondo de Investigacion Sanitaria
- Jhaver Research Foundation Limited
- University of Foggia
- Johnson and Johnson
- University of Rennes
- University of Antwerp
- Government of France
- University of Burgundy
- University of Franche-Comté
Organization Involved with Phase 2 Indications (7)
Organization Involved with Phase 1 Indications (3)
Organization Involved with Other Experimental Indications (8)
- Multicenter Clinical Study Group of Osaka, Colorectal Cancer Treatment Group
- New York University
- Capital Medical University
- Institute of Liver and Biliary Sciences, India
- Nasser Institute For Research and Treatment
- Multicenter Clinical Study Group of Osaka
- University of Caen-Normandie
- University of Lorraine